Latest News about IBB
Recent news which mentions IBB
Buying This Beaten-Down ETF Could Double Your Money Over the Next 5 Years
September 23, 2021
From Motley Fool
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
September 22, 2021
From Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
September 19, 2021
From Benzinga
Berkeley Lights calls short seller’s report ‘highly misleading,’ and stock bounces sharply off record low
September 17, 2021
From MarketWatch
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
September 17, 2021
From Benzinga
Drug Price Debate May Not Hinder Biotech ETFs After All
September 16, 2021
From ETF Trends
From Benzinga
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
September 15, 2021
From Benzinga
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
September 14, 2021
From Benzinga
Biotech Stocks Have Colds, but They Can Heal
September 13, 2021
From ETF Trends
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
September 12, 2021
From Benzinga
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
September 10, 2021
From Benzinga
Size Up SBIO Ahead of Biotech Rebound
September 09, 2021
From ETF Trends
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
September 09, 2021
From Benzinga
The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week
September 05, 2021
From Benzinga
3 Biotech Stocks That Soared to New Heights Last Week
September 05, 2021
From Motley Fool
Beat the market with this quant system that’s very bullish on stocks at record highs
September 04, 2021
From MarketWatch
Cassava Sciences CEO says ‘enormous profit motive’ behind N.Y. law firm’s fraud allegations
September 03, 2021
From MarketWatch
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
September 03, 2021
From Benzinga
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
September 02, 2021
From Benzinga
ETF Prime: Tom Lydon Talks Pros & Cons of Market Cap Weighting
September 01, 2021
From ETF Trends
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
September 01, 2021
From Benzinga
From Benzinga
From Benzinga
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week
August 29, 2021
From Benzinga
7 Best ETFs to Buy to Cover a Broad Spectrum of Opportunities
August 27, 2021
From InvestorPlace
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
August 27, 2021
From Benzinga
From Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.